Biotech Industry
topic on 5 shows · 13 statements across 10 episodes
No Priors 
Capital Allocators 
Catalyst 
How I Built This 
the a16z Podcast
13 statements about Biotech Industry, every show
Chan: Curing disease requires uniting academia and industry via non-profit neutrality
“The sort of neutral nonprofit nature of our work actually helps harness more people to enter this effort. And to actually achieve the mission of, like, understanding the totality of human biology and to cure, prevent, manage all diseases, you actually do need …”
Nuzhna: Biotech regulatory requirements have continuously increased since industry inception
“Since the birth of this industry, we only had increasing regulation over time.”
Nuzhna: Everyone in biotech will use AI within five years
“Everyone will be using AI and biotech industry five years from now.”
Nuzhna: FDA regulation has continuously increased except during the AIDS crisis
“Since the birth of this industry, we only had increasing regulation over time. I think there was like only one time in history of biotech where we made it easier to develop and approve new drugs. And that was during the ACE crisis where AIDS patients were just…”
Biotech funding cycle has shifted away from platforms back to products
“I think the pendulum always swings back and forth between platforms and products and back again. I think we're back in the product cycle”
Wong: Biotech is in its second-deepest and second-longest bear market ever
“So we are 18 months into a biotech bear market that's the second worst
Correction in the history of the industry, right?
The first being the obvious one, the genomics bubble bursting in 2000 to 2003.
It's second longest, second deepest.”
Lamont: By 2000 there were 3,000 public biotech companies and 5 approved products
“That there were 3000 public biotech companies, and only five approved products.”
Lipman: Synbio startups should prioritize niche, high-value markets
“You know, you always want to try to own a larger portion of a small market than try to own a small portion of a large market, at least at the outset. So I think, and that has been the tradition across the biotech industry and across synthetic biology is go for…”
Afeyan: Long biotech lifecycles prevent serial entrepreneurship, forcing internal talent creation
“In biotech, these companies have a half-life or a life cycle of, say, 10 years, 15 years. So people don't do one company after another. If they do one company after 1015 years and they succeed, they stop doing it. So you have to create the talent.”
Biotech underperformed tech and matched the S&P 500 over five years
“It's interesting that if you go look at the biotech industry relative or any of the small cap biotech industries relative to the NASDAQ or relative to the S&P, they've underperformed the NASDAQ, so they've underperformed tech the last four or five years. They'…”
Nate Chang: Biotech M&A deals totaled $123 billion in 2018
“So in 2018, the industry announced one hundred twenty three billion of MNA transactions.”